Cat.No：GM-87847AB

Product：Anti-DLL3-PBD(Dar2)[Rovalpituzumab tesirine]

GM-87847AB-100       100μg

GM-87847AB-1mg      1mg

Expression System                         CHO

Purity                                                    >95% as determined by SDS-PAGE

Aggregation                                       < 5% as determined by SEC-HPLC

Drug-to-Antibody Ratio (DAR) 1.0-2.0

Endotoxin                                            <1 EU/mg

Sterility                                                 0.22 μm Filtered

Target                                                    DLL3

Clone                                                     Rovalpituzumab tesirine

Alternative Names                         SCDO1

Source/lsotype                                Monoclonal Human IgG1 (Delta 447K), kappa

Application                                        Positive control of Cytotoxicity Assay

Description                                        Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate (ADC) designed specifically to target diseases with high expression of DLL3 (Delta-like ligand 3), with a particular focus on small cell lung cancer (SCLC). The mechanism of action of Rova-T combines the high specificity of the antibody with the potent cytotoxicity of its payload. By targeting DLL3 on the surface of tumor cells, Rova-T delivers its anticancer drug payload directly into these cells. Once Rova-T binds to DLL3 and is internalized by the tumor cell, the toxic payload (such as tesirine) is released, where it attaches to and damages the tumor cell’s DNA, causing double-strand breaks and ultimately triggering cell death. This design enables precise destruction of tumor cells while minimizing toxicity to normal tissues.

Formulation                                         20 mM Histidine, 100 mM NaCl, pH 6.0

Storage temp.                                     Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.